The ICEDORA study: clinical and demographic characteristics and treatment regimens of patients with HR+ HER2- locally advanced or metastatic breast cancer receiving CDK4/6 inhibitors in real clinical practice
Introduction. CDK4/6 inhibitors in combination with endocrine therapy (ET) are the current standard of care for patients with HR+ HER2- advanced and metastatic breast cancer (eBC and mBC). Evidence of the clinical efficacy of CDK4/6 inhibitors has been obtained in several randomized clinical trials...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Publishing House OKI
2025-07-01
|
| Series: | Реальная клиническая практика: данные и доказательства |
| Subjects: | |
| Online Access: | https://www.myrwd.ru/jour/article/view/105 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|